Pathology Analysis & Statistics, December 2014

24/7 Customer Support

Talk to Clare

+1 339 368 6001

Publishers

  • All
    • Global Data

All regions

1-30 of about 1 500 reports

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cance ...

  • Industries : Pathology
  • Countries : World
PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023

  • $ 6 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in ...

  • Industries : Pathology
  • Countries : Germany, Spain, Italy, France, United Kingdom, World, Europe
PharmaPoint: HER2-Positive Breast Cancer - US Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - US Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: HER2-Positive Breast Cancer - US Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women ...

  • Industries : Pathology
  • Countries : United States
PharmaPoint: HER2-Positive Breast Cancer - Japan Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - Japan Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: HER2-Positive Breast Cancer - Japan Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in ...

  • Industries : Pathology
  • Countries : Japan
PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in ...

  • Industries : Pathology
  • Countries : China
EpiCast Report: Colorectal Cancer - Epidemiology Forecast to 2023

EpiCast Report: Colorectal Cancer - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • December 2014
  • by Global Data

EpiCast Report: Colorectal Cancer - Epidemiology Forecast to 2023 Summary Colorectal cancer (CRC) is cancer that starts in the colon or the rectum. CRC has the third highest incidence among all cancers ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, China
EpiCast Report: Rheumatoid Arthritis - Epidemiology Forecast to 2023

EpiCast Report: Rheumatoid Arthritis - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • December 2014
  • by Global Data

EpiCast Report: Rheumatoid Arthritis - Epidemiology Forecast to 2023 Summary Rheumatoid arthritis (RA) is an autoimmune disease that causes inflammation of the joints. In RA, the body's immune system attacks ...

  • Industries : Pathology
  • Countries : Japan, India, China, World, Australia, Spain, Italy, France, Germany, United States, United Kingdom, Europe
EpiCast Report: Celiac Disease - Epidemiology Forecast to 2023

EpiCast Report: Celiac Disease - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • November 2014
  • by Global Data

EpiCast Report: Celiac Disease - Epidemiology Forecast to 2023 Summary Celiac disease is an autoimmune disease that occurs in individuals who consume gluten-containing foods but are intolerant to gluten, ...

  • Industries : Pathology
  • Countries : World, United States, Spain, Italy, France, Germany
EpiCast Report: Type 1 Diabetes - Epidemiology Forecast to 2023

EpiCast Report: Type 1 Diabetes - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • November 2014
  • by Global Data

EpiCast Report: Type 1 Diabetes - Epidemiology Forecast to 2023 Summary Type 1 diabetes is a type of diabetes that accounts for 10% of all diabetes cases. The condition occurs as a result of the autoimmune ...

  • Industries : Pathology
  • Countries : Canada, Japan, World, United States, Spain, Italy, France, Germany
EpiCast Report: Irritable Bowel Syndrome - Epidemiology Forecast to 2023

EpiCast Report: Irritable Bowel Syndrome - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • October 2014
  • by Global Data

EpiCast Report: Irritable Bowel Syndrome - Epidemiology Forecast to 2023 Summary Irritable Bowel Syndrome (IBS) is a chronic, relapsing gastrointestinal disorder that is characterized by abdominal discomfort ...

  • Industries : Pathology
  • Countries : Japan, World, Spain, Germany, United States, Italy, France
EpiCast Report: Cushing's Syndrome - Epidemiology Forecast to 2023

EpiCast Report: Cushing's Syndrome - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • October 2014
  • by Global Data

EpiCast Report: Cushing's Syndrome - Epidemiology Forecast to 2023 Summary Cushing's syndrome (CS) is a rare disorder caused by prolonged exposure to excess amounts of circulating free glucocorticoids, ...

  • Industries : Pathology
  • Countries : United States, World
EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2023

EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • October 2014
  • by Global Data

EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2023 Summary Dyslipidemia is a condition in which one or more of the serum lipid levels are abnormal. It is a well-established risk factor for cardiovascula ...

  • Industries : Pathology
  • Countries : Germany, Japan, China, World, United States
EpiCast Report: Allergic Conjunctivitis - Epidemiology Forecast to 2023

EpiCast Report: Allergic Conjunctivitis - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • October 2014
  • by Global Data

EpiCast Report: Allergic Conjunctivitis - Epidemiology Forecast to 2023 Summary Allergic conjunctivitis is an inflammation of the eye resulting from an allergic reaction to allergy causing substances (external ...

  • Industries : Pathology
  • Countries : World, United States, Spain, Italy, France, Germany
Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Herceptin (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : World, United States, Spain, Italy, France, Germany, Japan, China, United Kingdom, Europe
Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Perjeta (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : Japan, World, Spain, Italy, France, Germany, China, United States, United Kingdom, Europe
Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Kadcyla (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : Japan, World, Spain, Italy, France, Germany, China, United States, United Kingdom, Europe
Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Tykerb (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, China, Europe, United States, United Kingdom
Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Neratinib (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, China, World, United States, United Kingdom, Europe
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Global Clinical Trials Review, H2, 2014

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Global Clinical Trials Review, H2, 2014

  • $ 2 500
  • Industry report
  • November 2014
  • by Global Data

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Clostridium Difficile Infections (Clostridium ...

  • Industries : Pathology
  • Countries : World
Onychomycosis (Tinea Unguium) Global Clinical Trials Review, H2, 2014

Onychomycosis (Tinea Unguium) Global Clinical Trials Review, H2, 2014

  • $ 2 500
  • Industry report
  • November 2014
  • by Global Data

Onychomycosis (Tinea Unguium) Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Onychomycosis (Tinea Unguium) Global Clinical Trials Review, H2, 2014" provides data ...

  • Industries : Pathology
  • Countries : World
Cystic Fibrosis Global Clinical Trials Review, H2, 2014

Cystic Fibrosis Global Clinical Trials Review, H2, 2014

  • $ 2 500
  • Industry report
  • November 2014
  • by Global Data

Cystic Fibrosis Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Cystic Fibrosis Global Clinical Trials Review, H2, 2014" provides data on the Cystic Fibrosis clinical ...

  • Industries : Pathology
  • Countries : World, United States
Chagas Disease (American Trypanosomiasis) Global Clinical Trials Review, H2, 2014

Chagas Disease (American Trypanosomiasis) Global Clinical Trials Review, H2, 2014

  • $ 2 500
  • Industry report
  • November 2014
  • by Global Data

Chagas Disease (American Trypanosomiasis) Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Chagas Disease (American Trypanosomiasis) Global Clinical Trials Review, ...

  • Industries : Pathology
  • Countries : United States
Cutaneous Lupus Erythematosus Global Clinical Trials Review, H2, 2014

Cutaneous Lupus Erythematosus Global Clinical Trials Review, H2, 2014

  • $ 2 500
  • Industry report
  • October 2014
  • by Global Data

Cutaneous Lupus Erythematosus Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Cutaneous Lupus Erythematosus Global Clinical Trials Review, H2, 2014" provides data ...

  • Industries : Pathology
  • Countries : World
Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) Global Clinical Trials Review, H2, 2014

Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) Global Clinical Trials Review, H2, 2014

  • $ 2 500
  • Industry report
  • October 2014
  • by Global Data

Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Chronic Cutaneous Lupus Erythematosus ...

  • Industries : Pathology
  • Countries : World
Plaque Psoriasis (Psoriasis Vulgaris) Global Clinical Trials Review, H2, 2014

Plaque Psoriasis (Psoriasis Vulgaris) Global Clinical Trials Review, H2, 2014

  • $ 2 500
  • Industry report
  • October 2014
  • by Global Data

Plaque Psoriasis (Psoriasis Vulgaris) Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Plaque Psoriasis (Psoriasis Vulgaris) Global Clinical Trials Review, H2, 2014" ...

  • Industries : Pathology
  • Countries : World
Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2014

Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2014

  • $ 2 500
  • Industry report
  • October 2014
  • by Global Data

Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2014" provides data on ...

  • Industries : Pathology
  • Countries : World
Orion Genomics LLC - Product Pipeline Analysis, 2014 Update

Orion Genomics LLC - Product Pipeline Analysis, 2014 Update

  • $ 750
  • Company report
  • December 2014
  • by Global Data

Summary Orion Genomics LLC (Orion Genomics) is a provider of epigenetic research tools and molecular diagnostic products. Its products include colon cancer risk test, bladder cancer screening and lung ...

  • Industries : Pathology
  • Countries : United States
Vitatex Inc. - Product Pipeline Analysis, 2014 Update

Vitatex Inc. - Product Pipeline Analysis, 2014 Update

  • $ 750
  • Company report
  • December 2014
  • by Global Data

Summary Vitatex Inc. (Vitatex) is a biotechnology company. The company research and develops new immunochemistry assays and reagents for the in-vitro diagnostic market. Its research products include Vita-Assays, ...

  • Industries : Pathology
  • Countries : United States
Ascenion GmbH - Product Pipeline Analysis, 2014 Update

Ascenion GmbH - Product Pipeline Analysis, 2014 Update

  • $ 750
  • Company report
  • December 2014
  • by Global Data

Summary Ascenion GmbH (Ascenion) is a life science service company. It provides science and research promotion services. The product line of the company includes therapeutic, diagnostic, medical technology, ...

  • Industries : Pathology
  • Countries : Japan
ProCelo AS - Product Pipeline Analysis, 2014 Update

ProCelo AS - Product Pipeline Analysis, 2014 Update

  • $ 750
  • Company report
  • December 2014
  • by Global Data

Summary ProCelo AS (ProCelo) is a medical device company. The company develops and markets diagnostic assays for detection of bacterial infections. Its ProCt product is a diagnostic kit which is used fo ...

  • Industries : Pathology
  • Countries : United States, Norway

20 Companies

Read our Company Profiles

GlaxoSmithKline P.L.C.

United States

Johnson and Johnson

United States

Eli Lilly and Co.

United States

C.R. Bard Inc.

United States

Novartis Inc.

Switzerland

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.